Document text
Principal Investigator: Vijaya Mohan Rao Lella
Organization: UNIVERSITY OF TEXAS HLTH CTR AT TYLER
Fiscal Year: 2022
Award: $183,750
Funding agency: National Institute of Allergy and Infectious Diseases
Emerging evidence indicates that the novel SARS-CoV-2 infection is associated with a high incidence of
thrombotic complications. Thrombotic complications in COVID-19 patients are found to be life-threatening.
Elevated D-dimers and disseminated intravascular coagulation (DIC) are strong predictors of mortality in
hospitalized COVID-19 patients. Consistent with the major influence of coagulopathy in the pathogenesis of
COVID-19, anticoagulant treatments were shown to improve the survival of critically ill COVID-19 patients.
Although the association of coagulation abnormalities with COVID-19 is evident, the underlying mechanism
for these abnormalities is unknown. Many diseases, including viral infections, induce tissue factor (TF)
expression in monocytes/macrophages and endothelial cells and release TF+ extracellular vesicles (EVs) into
circulation. Our recent studies suggest that alterations in sphingomyelin metabolism greatly influence TF
activity by controlling TF encryption and decryption, and generation of TF+ EVs. We hypothesize that
hypercoagulability associated with SARS-CoV-2 infection stems from increased TF activity and the release
of TF+ EVs into the circulation following the infection. We further hypothesize that spike protein-induced
activation of acid sphingomyelinase (ASMase) is responsible for increased TF activity via TF decryption and
generation of TF+ EVs. We propose that treatment with ASMase functional inhibitors will attenuate
coagulopathy associated with SARS-CoV-2 infection. The overall goal of the proposal is to obtain a proof of
concept to the above hypothesis. Our aims are: (i) determine the mechanism by which the SARS-CoV-2 spike
protein increases TF activity and generates TF+ EVs; (ii) define the role of SARS-CoV-2’s spike protein on
activation of TF-induced coagulopathy and microvascular thrombosis in hACE2 transgenic mice and
determine whether ASMase functional inhibitors attenuate SARS-CoV-2-induced coagulopathy. In the
proposed studies, we will use both SARS-CoV-2 spike protein pseudovirus and authentic SARS-CoV-2
infections in cell model systems and a murine model system. Our proposed studies will identify potential
mechanisms by which SARS-CoV2 infection induces hypercoagulability and thrombosis. They will also
provide clues for the development of novel, targeted, and safe interventions to treat hypercoagulability in
COVID-19 patients, which could help to reduce mortality. We have more than thirty years of experience
working on TF and have all the tools and resources, and technical expertise to complete the proposed studies
successfully.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><ARDS><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Anticoagulant Agents><Anticoagulant Drugs><Anticoagulants><Attenuated><Biologic Models><Biological Models><Blood Circulation><Blood Coagulation Disorders><Blood Coagulation Factor III><Blood Neutrophil><Blood Polymorphonuclear Neutrophil><Blood monocyte><Bloodstream><CD142 Antigens><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 S protein><COVID-19 infected patient><COVID-19 infection><COVID-19 pathogenesis><COVID-19 patient><COVID-19 positive patient><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19><COVID19 S protein><COVID19 infection><COVID19 pathogenesis><COVID19 patient><COVID19 positive patient><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><Cell Body><Cell membrane><Cell model><Cell surface><Cells><Cellular model><Circulation><Clotting><CoV-2><CoV2><Coagulation><Coagulation Disorder><Coagulation Factor III><Coagulation Process><Coagulin><Coagulopathy><Complement Activation><Consumption Coagulopathy><Critical Illness><Critically Ill><Cytoplasmic Membrane><D-dimer><D-dimer fibrin><D-dimer fragments><Da Nang Lung><Data><Demethylimipramine><Desipramine><Desmethylimipramine><Development><Disease><Disorder><Disseminated Intravascular Coagulation><Dysfunction><Endothelial Cells><Endothelium><Enzyme Gene><Enzymes><Epithelial Cells><FDA approved><Factor III><Fibrin fragment D><Functional disorder><Generations><Glomerular Procoagulant Activity><Goals><Hemostatic Agents><Hemostatics><Human><Hydrolysis><Hypercoagulability><Hypoxemic Respiratory Failure><Hypoxic Respiratory Failure><Imidobenzyle><Imipramine><Imizin><Incidence><Infection><Inflammation><Inflammatory><Intermediary Metabolism><Intervention><Intervention Strategies><Lentivirinae><Lentivirus><Life><Lung><Lung Respiratory System><MOF syndrome><Marrow Neutrophil><Marrow monocyte><Metabolic Processes><Metabolism><Model System><Modern Man><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Mφ><Neutrophilic Granulocyte><Neutrophilic Leukocyte><Norchlorimipramine><Pathogenesis><Pathologic><Patients><Phosphatides><Phospholipids><Physiopathology><Plasma Membrane><Platelet Activation><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Proteins><Prothrombinase><Publications><Receptor Cell><Receptor Protein><Reporting><Research Resources><Resources><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Shock Lung><Short interfering RNA><Small Interfering RNA><Sphingomyelins><Stiff lung><Stimulus><Technical Expertise><Thromboembolism><Thrombophilia><Thromboplastin><Thrombosis><Tissue Factor><Tissue Factor Procoagulant><Tissue Thromboplastin><Tofranil><Transgenic Mice><Tricyclic Antidepressant Drugs><Tricyclic Antidepressants><Tricyclic Antidepressive Agents><Up-Regulation><Upregulation><Urothromboplastin><Venous><Viral Diseases><Virus Diseases><Virus-Lenti><Wuhan coronavirus><acid sphingomyelinase><base><bleeding disorder><blood thinner><cell type><clotting disorder><complement pathway regulation><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 pathogenesis><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><developmental><encryption><experience><extracellular><extracellular vesicles><fibrin fragment D-dimer><fibrin fragment D1 dimer><fibrin fragment DD><hCoV19><improved><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibitor><interventional strategy><macrophage><monocyte><mortality><mouse model><multiorgan failure><multiple organ system failure><murine model><nCoV2><neutrophil><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathophysiology><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><plasmalemma><pulmonary><receptor><response><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><siRNA><social role><stem><technical skills><thromboembolic complications><thrombopoiesis inhibitor><thrombosis complications><thrombotic complications><thrombotic disease><thrombotic disorder><tool><viral infection><virus infection><virus-induced disease><wet lung>